Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.

MLA

Di Maida, Fabrizio, et al. “Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.” Clinical Genitourinary Cancer, vol. 17, no. 4, Aug. 2019, pp. e751–58. EBSCOhost, https://doi.org/10.1016/j.clgc.2019.04.008.

APA

Di Maida, F., Mari, A., Scalici Gesolfo, C., Cangemi, A., Allegro, R., Sforza, S., Cocci, A., Tellini, R., Masieri, L., Russo, A., Carini, M., Minervini, A., & Serretta, V. (2019). Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression. Clinical Genitourinary Cancer, 17(4), e751–e758. https://doi.org/10.1016/j.clgc.2019.04.008

Chicago

Di Maida, Fabrizio, Andrea Mari, Cristina Scalici Gesolfo, Antonina Cangemi, Rosalinda Allegro, Simone Sforza, Andrea Cocci, et al. 2019. “Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cancer: A New Potential Tool to Identify Patients at Higher Risk of Disease Progression.” Clinical Genitourinary Cancer 17 (4): e751–58. doi:10.1016/j.clgc.2019.04.008.